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Nanoparticles present enormous surface areas and are found to
enhance the rate of protein fibrillation by decreasing the lag time
for nucleation. Protein fibrillation is involved in many human
diseases, including Alzheimer’s, Creutzfeld-Jacob disease, and
dialysis-related amyloidosis. Fibril formation occurs by nucleation-
dependent kinetics, wherein formation of a critical nucleus is the
key rate-determining step, after which fibrillation proceeds rap-
idly. We show that nanoparticles (copolymer particles, cerium
oxide particles, quantum dots, and carbon nanotubes) enhance the
probability of appearance of a critical nucleus for nucleation of
protein fibrils from human 2-microglobulin. The observed shorter
lag (nucleation) phase depends on the amount and nature of
particle surface. There is an exchange of protein between solution
and nanoparticle surface, and 2-microglobulin forms multiple
layers on the particle surface, providing a locally increased protein
concentration promoting oligomer formation. This and the short-
ened lag phase suggest a mechanism involving surface-assisted
nucleation that may increase the risk for toxic cluster and amyloid
formation. It also opens the door to new routes for the controlled
self-assembly of proteins and peptides into novel nanomaterials.
amyloid  nanotoxicology  surface-assisted nucleation
In the coming decades nanomaterials are considered likely torevolutionize many arenas, including information technology
and biomedical industries. Nanomedicine and nanodiagnostics
are believed to offer hope with some of the most intractable
challenges in human health (1). However, relatively little is
known about the potential biological risks from nanoparticles,
and growing awareness of these issues has led to the emergence
of the field of nanotoxicology (2–4). There is little evidence as
yet to imply that nanoscale objects introduce the potential for
disease, apart from the long-known induction of the aggressive
cancer mesothelioma by nanorods of blue asbestos (5). Many
nanoparticles are small enough to access all parts of the body,
including the brain (6, 7). Entry into cells can occur via receptor-
mediated endocytosis (8), and there is an established in vivo link
between nanoparticles and reactive oxygen production (9, 10).
However, the challenges that these new nanomaterials may
present to the organism remain unresolved. Here, we highlight
the potential for nanoparticles to promote protein assembly into
amyloid fibrils in vitro by assisting the nucleation process. Our
findings may provide new tools toward an understanding of
nucleation mechanisms. We also note that nanoparticles poten-
tially open the door to new routes of controlling biological
self-assembly for use in nanomedicine, arising from a novel and
general surface-mediated nucleation mechanism.
Nanoparticles are almost invariably coated with proteins when
they enter a biological f luid (11–14), with consequent structural
and functional perturbations of the surface-bound state of the
protein (3). Proteins may be bound in a native-like or denatured
form depending on protein surface charge, hydrophobicity, and
intrinsic stability, but also depending on particle characteristics
(15, 16). Nanoparticles possess enormous surface-to-volume
ratios (for example, there is 800 m2 of surface area per liter of
a 1 wt% dispersion of 70-nm particles). The potentially high
concentration of proteins adsorbed at the particle surface,
combined with the low dimensionality of the surface, can
enhance the probability of partially unfolded proteins coming
into frequent contact, leading to faster clustering, or even
radically new protein clusters (17, 18). These properties of
nanoparticles can influence protein self-assembly reactions, with
the potential that important biological processes may be per-
turbed, or that diseases involving protein misfolding and assem-
bly may be enhanced. One important phenomenon involving
protein self-assembly is the class of human diseases named
amyloidoses. Currently, 30 different proteins and peptides are
known to cause human amyloid disease (for reviews see refs.
19–23). These diseases involve self-assembly of soluble proteins
into large insoluble fibrils through nucleation-dependent assem-
bly, often via the formation of oligomeric structures that possess
toxic properties (24, 25). It has been shown that surfaces
presented by lipid bilayers (26), collagen fibers (27), polysac-
charides (28, 29), and other liquid–air, liquid–solid, or liquid–
liquid interfaces (30, 31) can have specific and significant effects
in promoting amyloid formation. These observations suggest
that interactions with different surfaces could promote protein
self-assembly into amyloid fibrils and enhance protein confor-
mational changes associated with other protein misfolding
diseases.
Dialysis-related amyloidosis, involving the self-assembly of the
human protein 2-microglobulin (2m; Fig. 1), is one of the many
known amyloid diseases. It occurs in all patients undergoing
long-term hemodialysis (32, 33) and is typified by deposition of
amyloid plaques in skeletal tissue (34). 2m fibril growth occurs
via multiple pathways (35, 36), and the fibrils formed through
each route have distinct morphology. A seed-independent ho-
mogeneous nucleation-and-growth mechanism, requiring high
concentration of the monomer only, predominates at pH values
3 (37, 38). Under these conditions the protein is partially or
more extensively unfolded, depending on the precise conditions
of pH, temperature, and ionic strength (39, 40). Nucleation is a
stochastic event, and fibrillation by this mechanism is charac-
terized by a lag phase, after which fibril formation proceeds
rapidly to completion. Fibril formation of 2m has also been
observed at neutral pH where the protein is predominantly
native (29, 41). At this pH, fibrillation of the wild-type protein
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requires the addition of seeds (29) and is enhanced by SDS (42),
glycosaminoglycans (28, 29), and collagen (27). However, the
precise molecular mechanism(s) by which these highly charged
molecules stimulate assembly is not known.
Here, we show that uncharged polymeric (and other) nano-
particles with different surface properties increase the rate of
protein fibril nucleation of 2m dramatically in the absence of
preformed specific seeds. The polymer particles were chosen as
models for our studies because they are well controlled in size
and purity. They have previously been reported to have low
toxicity (43, 44), and similar particles are currently being inves-
tigated as drug delivery devices in vivo (45). They also allow the
size (curvature) and hydrophobicity of the nanoparticle surfaces
to be varied systematically, allowing elucidation of the control
parameters for nucleation and growth in a novel and powerful
manner. To highlight the importance of the issue, and add
perspective, we also present results for a selected set of other
nanoparticles (quantum dots, carbon nanotubes, and cerium
oxide particles) that are intended for early industrial applications
of nanotechnology.
Results and Discussion
To examine the role of nanoparticles in protein fibrillation, the
self-assembly of 2m into amyloid-like fibrils was studied at pH
2.5 and 37°C as these conditions lead to the quantitative for-
mation of well characterized amyloid fibrils in the absence of
amorphous aggregation (46, 47). The protein concentration was
40, 80, or 125 M (as determined by absorbance at 277 nm) in
6, 10, or 20 mM sodium phosphate buffer, pH 2.5, at low, 40, or
50 mM NaCl [see supporting information (SI) Table 1]. Under
these conditions 2m is unfolded and lacks residual ordered
secondary structure, yet remains compact (Rh increases by
20% relative to native 2m) by virtue of the single disulfide
bond that remains intact in the low pH denatured state (40). For
all experiments gel filtration was performed immediately before
setting up the experiments to isolate the protein monomer and
remove any traces of oligomers or aggregates. Buffer stock was
added to the monomer solution, the pH was checked on a
thoroughly rinsed pH electrode, and the solution was filtered
(0.2-m filter) before incubation at 37°C with or without 0.01
mg/ml copolymer nanoparticles. The resulting solutions corre-
spond to 90 pM 70-nm particles and 4 pM 200-nm particles.
The copolymer particles weremade fromN-isopropylacrylamide
(NIPAM) and N-tert-butylacrylamide (BAM) at two different
ratios of NIPAM/BAM (85:15 or 50:50) and a small amount of
cross-linker and were synthesized in SDS micelles to control their
size to 70 or 200 nm. Particle sizes were determined by using
dynamic light scattering and electron microscopy. The 50:50
NIPAM/BAM nanoparticles are significantly more hydrophobic
than the 85:15 NIPAM/BAMparticles (44). Particles were dialyzed
for several weeks, with the dialysate being checked for conductance
until it was the same as pureMilliQwater. The purity of the particles
was also checked to ensure the absence of monomer and SDS by
NMR (see SI Text for further information). Our initial experiments
were performed in black 96-well plates and contained four kinds
of copolymer nanoparticles (two sizes and two comonomer ratios)
in addition to wells without particles. Subsequent experiments
were set up in groups of 48–120 samples made from the same
solution, some of which were supplemented with the copolymer
nanoparticles. For these experiments a 0.5-ml sample was shaken in
a 1.5-ml Eppendorf tube at 250 rpm in close to horizontal orien-
tation. To monitor the appearance and growth of fibrils, aliquots
from the tubes were taken at different time points, and the
fluorescence of thioflavin T was measured. Parallel experiments
using intrinsic tryptophan emission or anisotropy as probes showed
that the lag times correspond to those measured by using thioflavin
T fluorescence.
Our initial experiments at low ionic strength (10 mM sodium
phosphate buffer, pH 2.5) in plate format (Fig. 2A) showed a
dramatic increase in the rate of fibrillation in the presence of
nanoparticles. Indeed, fibril formation was completed within
1,800 min (in the presence of 85:15 particles) or 3,500 min
(using 50:50 particles); in the absence of nanoparticles the lag
phase is so long that few, if any, fibrils were formed during the
3,500-min time course of this experiment. Negative stain elec-
tron microscopy (Fig. 2B) shows that the fibrils formed in the
presence of particles have a long, straight morphology, which is
typical of fibrils formed in the absence of nanoparticles under
these conditions (48). Moreover, most of the fibrils are free in
solution and not connected to the particles.
To obtain sufficient data for statistical analysis of the effect of
the nanoparticles on the growth kinetics and eliminate irrepro-
ducibility caused by small differences in solution conditions, a
larger collection of 732 experiments with or without copolymer
nanoparticles was set up in groups of up to 120 samples in
Eppendorf tubes (see SI Text for details). One group of 120
samples was set up at the same low-salt conditions as the initial
experiments, and all samples with nanoparticles were found to
form fibrils more rapidly than those lacking particles (data not
shown). The remaining 612 fibrillation experiments were per-
formed at pH 2.5 in the presence of 40 or 50 mM NaCl, under
which conditions the rate of fibrillation was increased (35, 47),
allowing for the collection of more data in a reasonable time.
Under these conditions the presence of 0.01 mg/ml nanoparticles
was also observed to enhance the rate of fibrillation, principally
by decreasing the length of the lag phase (Fig. 3 A–D). By
contrast, the rate of fibril elongation appears to be largely
unaffected by the presence of the nanoparticles. The relative
effect of 70- and 200-nm particles, which differ in total amount
of exposed surface area and its curvature, was found to vary with
solution conditions such as protein and salt concentration. A
complex dependence on protein concentration, exposed surface
area, pH, salt concentration, etc. is expected (49).
The detailed molecular mechanism of nucleation on the
nanoparticle surface remains elusive, but could involve the
particles increasing the probability of homogeneous nucleation
events by providing a locally higher concentration of monomers.
Alternatively, the interaction with particle surfaces could ac-
Fig. 1. Size comparison of monomeric 2m (seeUpper Left for enlargement)
with nanoparticles. One protein molecule is placed on each particle in scale for
size comparison with nanoparticles of 70 nm (Lower Left) and 200 nm (Right).
This figure was prepared with Molmol (58).
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tively promote an appropriate conformational change. None-
theless, the dependence of the length of the lag phase on the
amount of surface and its characteristics (relative hydrophobic-
ity; Figs. 2 and 3) suggests that the nucleation mechanism
involves the association of the protein with the particle surface.
To assess the effect of the surface on nucleation in more detail,
the interaction of 2m with the different nanoparticle surfaces
was studied by using surface plasmon resonance (SPR). To
achieve this, the four kinds of copolymer nanoparticles were
immobilized onto gold surfaces by using particles modified to
contain a free thiol group (see SI Text) (50), and the binding and
dissociation of 2m from the surfaces was monitored (Fig. 4).
The total amplitude of the 2m binding, obtained by curve fitting
to the association and dissociation data (see SI Text), corre-
sponds to 1  105 protein molecules per 200-nm 85:15 particle.
A 200-nm particle has a surface area of 1.3  1013 m2. In its
native conformation, 2m has a cross-sectional area of 0.6–1.3
1017 m2 depending on orientation (it is an oblate spheroid; Fig.
1) meaning that up to 2  104 protein molecules would fit in a
single layer on a 200-nm particle. At pH 2.5 2m is denatured
(46) but the hydrodynamic radius of the protein is increased by
only 20% (40). Although the results from the SPR are only
semiquantitative, they indicate, nonetheless, that several layers
of 2m (but a discrete number) are associated with the particles.
Fig. 2. 2m fibrillation in the presence of nanoparticles. (A) Kinetics of 2m fibrillation. Thioflavin T fluorescence as a function of time for 80 M (1 mg/ml) 2m
at 37°C in 10 mM sodium phosphate buffer, pH 2.5, with 0.02% NaN3, without (black) or with 0.01 mg/ml nanoparticles with 85:15 (blue) or 50:50 (red)
NIPAM/BAM ratio is shown. Smaller symbols are used for 70-nm particles. (B) Negative stain electron microscopy image of fibers grown in the presence of 70-nm
85:15 NIPAM/BAM copolymer nanoparticles. (Scale bar: 100 nm.)
Fig. 3. Kinetics of2m fibrillation. (A and E) Histograms of observed lag times. (B,D, and F) Thioflavin T fluorescence as a function of time showing kinetic traces
for all samples in each group. (C) The average of all samples of each kind shown inD. (A and B) Forty micromolar 2m at 37°C in 20 mM sodium phosphate buffer,
pH 2.5, with 50 mM NaCl and 0.02% NaN3. (C andD) Forty micromolar 2m at 37°C in 20 mM sodium phosphate buffer, pH 2.5, with 40 mM NaCl and 0.02% NaN3.
(E and F) Forty micromolar 2m at 37°C in 20 mM sodium phosphate buffer, pH 2.5, with 50 mM NaCl and 0.02% NaN3. Color coding of kinetic traces and
histograms: blue (0.01 mg/ml 70-nm 85:15 NIPAM/BAM particles), cyan (0.01 mg/ml 200-nm 85:15 NIPAM/BAM particles), red (0.01 mg/ml 70-nm 50:50
NIPAM/BAM particles), pink (0.01 mg/ml 200-nm 50:50 NIPAM/BAM particles), orange (100 nM 16-nm quantum dots), green (0.01 mg/ml 6-nm-diameter
multiwalled carbon nanotubes), yellow (0.01 mg/ml 16-nm cerium oxide particles), and black (samples without particles).




















Two kinetic processes are needed to fit the association and
dissociation kinetics obtained from the SPR experiments (see
Fig. 4), suggesting that more than one population of 2m is
bound to the surface, in agreement with earlier studies of
fibronectin binding to copolymer films (51) and BSA binding to
citrate-coated gold nanoparticles (52). The two rate constants
for dissociation of 2m from the 200-nm 85:15 nanoparticles
differ by about two orders of magnitude (1  104 s1 and 2 
106 s1), whereas the two association rate constants are 20 and
140 M1s1. The rates of dissociation are significantly faster on
the more hydrophobic 200-nm particles (off-rate constants 8 
103 s1 and 5  104 s1), in agreement with other plasma
proteins (50), but the stoichiometry appears to be similar (8 
104 protein molecules per particle), and the two association rate
constants are 15 and 2,000 M1s1, indicating weaker binding to
the more hydrophobic surface. We see no variation in the rate
constants with particle size (70 or 200 nm).
To analyze the effect of the surfaces on the conformational
properties of 2m, tryptophan fluorescence emission spectra of
the protein were acquired in the presence of the different
particles. The resulting data revealed an 8-nm blue shift in
tryptophan fluorescence emission maximum for surface-bound
2m on the 50:50 NIPAM/BAM particles (Fig. 5), consistent
with burial of the tryptophan residues in the more hydrophobic
environment of the particle surface. The data for 2m titrated
into the particle solution have the appearance of a binding curve.
A simple binding model with a single type of independent sites
can be fitted to these data, yielding a stoichiometry of 2,200 
1,000 2m per 70-nm particle and an apparent affinity of
8  4105 M1. The surface of a 70-nm particle would accom-
modate a maximum of 2,500 protein molecules. The fluores-
cence data hence suggest that only the innermost layer(s) of
particle-bound proteins experiences a blue shift in fluorescence,
consistent with burial of Trp toward the hydrophobic groups on
the particle surface. This interpretation is supported by the fact
that a smaller blue shift is observed with the more hydrophilic
85:15 particles (data not shown). By isothermal titration calo-
rimetry, we observe a positive H, indicating an endothermic
process for the binding of the first layer of 2m that binds to the
nanoparticles (Fig. 6), whereas the subsequent layers give no
signal (see SI Text for experimental details). Thus, for all layers
(and predominantly for the innermost layer) association with the
nanoparticles is entropy-driven, possibly because of desolvation
of the particle and protein surface groups.
The presence of multiple layers of 2m on the nanoparticles,
together with the off-rate constants determined for 2m from
the nanoparticle surfaces, indicates that multiple binding and
dissociation cycles occur during the lag phase. These observa-
tions provide a rationale by which the particles could enhance
the probability of appearance of a critical nucleus (an oligomer
or cluster that is in the fibrillation-competent form) for homo-
geneous (seed-free) nucleation. As a consequence of their
hydrophobic nature, therefore, we propose that the nanopar-
ticles enrich the population of protein clusters, and possibly also
alter their structural properties (53), thereby enhancing self-
assembly. Earlier studies of 2m in the absence of nanoparticles
indicate that fibrillation is preceded by the formation of dimers,
trimers, and tetramers (54), although it is not known if any of
these oligomers represent the critical nucleus. Further studies of
fibrillation using different proteins or peptides, representing
several structural classes, combined with systematic alteration of
the surface properties of the nanoparticles, therefore, offer a
new opportunity to provide molecular insights into the nucle-
ation process itself.
Although this study uses a tailored set of model nanoparticles,
it is interesting to ask whether the observed effects also arise with
other kinds of nanoparticles, especially those with the most
immediately proposed industrial applications. Therefore, we
performed one set of 116 experiments in tubes for 2m alone and
in the presence of 16-nm hydrophilic polymer-coated quantum
dots (55), 16-nm cerium oxide particles, or multiwalled carbon
Fig. 4. SPR data for 2m associating to and dissociating from 200-nm 15:85
NIPAM/ BAM nanoparticles (blue) or 200-nm 50:50 NIPAM/BAM nanoparticles
(red) linked to gold via a thiol group. The protein was injected between 0 and 30
min at constant concentration of 40M and followed by a constant buffer flow.
The black curves were fitted to the association and dissociation data by using Eqs.
1 and 2 in SI Text. (Inset) An expansion of the dissociation data (blue) with fitted
curve (black) for the 200-nm 15:85 NIPAM/BAM nanoparticles.
Fig. 5. Change in2m conformation in the presence of nanoparticles. (A) Trp
fluorescence spectra of 2m titrated into buffer (dashed lines) and into a
solution with 70-nm 50:50 NIPAM/BAM nanoparticles (solid lines). (B) Fluo-
rescence intensity at 335 nm versus 2m concentration. 2m titrated into
buffer (black triangles) fitted by a straight line, and 2m titrated into 70 nm
50:50 nanoparticles (red filled circles) fitted by a 1:1 binding curve is shown.
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nanotubes of 6 nm diameter (56). All of these particles were
found to increase the rate of fibrillation by shortening the lag
phase (Fig. 3 E and F), consistent with the view that nucleation
is a surface-assisted process.
A wide variety and large amounts of new ‘‘surfaces’’ will f low
from the diversity of engineered nanoparticles that are emerging
for use in industrial applications, increasing the likelihood of
human exposure to nanoparticles. It remains to be seen whether
the enormous enhancements in nucleation rate for protein
fibrillogenesis demonstrated in this work also occurs in vivo or in
more complex biological f luids where competitive binding may
screen the nucleation surface.
Our findings also suggest other more positive future directions
in which nanoparticles could be used to as a ‘‘combinatorial’’
reaction space on which to form new protein assemblies or to
enhance and control the rate of protein or peptide self-assembly
into amyloid-like materials with novel biotechnological proper-
ties as materials with therapeutic roles. Finally, and perhaps most
importantly, these particles (by the remarkable amount of
control of time scales and cluster enrichment) offer a new and
powerful route to define the molecular forces and events that
govern protein nucleation mechanisms.
Materials and Methods
Protein.Human2mwas initially expressed inEscherichia coliBL21
pLysS Star from a synthetic gene (with codons optimized for
expression in E. coli) prepared from overlapping oligonucleotides
as described in SI Text and SI Fig. 7. The protein was purified from
inclusion bodies by using ion exchange steps before and after
refolding and one gel filtration step, as described in SI Text. Care
was taken to avoid deamidation of the protein by limiting the time
spent between harvest of the cells and elution from the first
exchange column. The gel filtration step was performed to obtain
pure monomer just before setting up fibrillation experiments, and
any traces of oligomers and aggregates were removed.
Nanoparticles.NIPAM/BAMcopolymer particles of 70 and 200 nm
diameter and with two different ratios of the comonomers (85:15
and 50:50 NIPAM/BAM) were synthesized in SDS micelles as
described byWu et al. (57) with details given in SI Text. Hydrophilic
polymer-coated quantum dots of 16-nm diameter (55) were pro-
vided by W. Parak (Ludwig Maximilians University, Munich,
Germany). Cerium oxide particles of 16 nm diameter and multi-
walled carbon nanotubes of 6 nm diameter (56) were provided by
J. Holmes and M. Morris (University of Cork, Cork, Ireland) and
J. Hanrahan of Glantreo Ltd. (Cork, Ireland).
Thiol-Linked Nanoparticles for SPR Studies. NIPAM/BAM/acrylic
acid copolymer nanoparticles with maximum one carboxyl group
per particle surface were synthesized and modified to provide
maximum one thiol group per particle as described in ref. 50 and
SI Text.
Fibrillation Experiments in Plates. 2m at 80 M (1 mg/ml) was
incubated at 37°C in 10 mM sodium phosphate buffer, pH 2.5, with
0.02% NaN3, and 10 M thioflavin T without or with 0.01 mg/ml
nanoparticles in a multiwell plate. The plates were agitated con-
tinuously in an incubator at 200 rpm. The thioflavin T fluorescence
was measured at 480 nm with excitation at 440 nm.
Fibrillation Experiments in Tubes. In the vast majority of fibrillation
experiments,2m fibrillationwas studied at 37°C in the absence and
presence of nanoparticles under a set of solution conditions in
Eppendorf tubes. The protein concentration was 40 or 125 M (as
determined by absorbance at 277 nm), in 6, 10, or 20 mM sodium
phosphate buffer, pH 2.5, with 0.02% NaN3, with 0, 40, or 50 mM
NaCl. The protein solutionwas subjected to gel filtration just before
setting up the experiments to isolate the protein monomer and
remove any traces of oligomers or aggregates. Buffer stock was
added to the monomer solution, pH was checked on a thoroughly
rinsed pH electrode, and the solution was then filtered [0.2-m
filter (Minisart; Sartorius, Goettingen, Germany), which was
washed with buffer before the sample] before it was incubated at
37°C with or without 0.01 mg/ml copolymer nanoparticles. The
experiments were set up in groups from the same solution, with
48–120 samples in each group out ofwhich one fractionwaswithout
nanoparticles and other fractions were supplemented with nano-
particles. In total, 732 samples were followed for experiments with
and without copolymer nanoparticles, and 116 samples were fol-
lowed in the experiments with and without carbon nanotubes,
cerium oxide particles, and quantum dots. Each sample of 0.5 ml
was shaken in a 1.5-ml Eppendorf tube at 250 rpm with close to
horizontal orientation. To monitor the appearance and growth of
fibrils, aliquots from the tubes were taken at different time points
and added to a black 96-well plate, and the thioflavin T fluores-
cence (20 M thioflavin T added) was measured at 475 nm with
excitation at 435 nm in a plate reader.
Electron Microscopy. Negative stain electron microscopy images
were taken in a CM-10 microscope (Philips, Eindhoven, The
Netherlands). Sample grids were prepared as described (46).
Fluorescence Titrations. 2m at different concentrations ranging
from 0 to 4 M was mixed with 0.9 nM 70-nm 50:50 or 85:15
NIPAM/BAM particles in 10 mM sodium phosphate buffer, pH
2.5, with 50 mM NaCl and 0.02% NaN3 at 37°C. Tryptophan
fluorescence was excited at 280 nm (slit 2.5 nm), and spectra
were recorded between 300 and 420 nm (slit 5 nm), with further
details in SI Text.
SPR Experiments. Thiol-linked nanoparticles were conjugated to
gold as described in ref. 50 and SI Text. SPR studies of 2m
associating to and dissociating from surface-tethered nanopar-
ticles were performed with a BIAcore 3000 instrument (BIA-
Fig. 6. Isothermal titration calorimetry data at 5°C from titration of2m into
a solution containing 70-nm 50:50 NIPAM/BAM nanoparticles. The protein
concentration was 160 M, and the particle concentration was 1 mg/ml. Each
injection was 15 l with a total of 19 injections. (Upper) Raw data. (Lower)
integrated data. The black line shows the fitted curve assuming a simple 1:1
binding model with one kind of sites (Eq. 3 in SI Text), with the parameter
values H  45 kJ/mol and KA  4  105 M1, n  1,040.




















core, Uppsala, Sweden) at 25°C in 10 mM sodium phosphate
buffer, pH 2.5, with 50 mMNaCl as described in SI Text. In short,
2m was injected for 30 min to study the association kinetics.
After 30 min, buffer was flown over the sensorchip surface for
10–24 h. The data analysis is described in SI Text. In the
calculation of the amount of bound proteins per particle, both
protein and nanoparticles were assumed to yield a signal of 1
response unit for a bound amount of 1 pg/mm2.
Isothermal Titration Calorimetry. 2m was titrated from a 160 M
stock into a 9 nM (1 mg/ml) solution of 70-nm 50:50 or 85:15
NIPAM/BAM nanoparticles in 10 mM sodium phosphate
buffer, pH 2.5, with 50 mM NaCl at 5°C. Details and data
analysis are given in SI Text.
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